Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07481526

A Prospecitve Multicenter, Observational Registry Study

This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Kidney Disease Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Hospital Affilicated with Fudan University

Shanghai, China

Location status: Recruiting

About this study

To ensure a nationally representative cohort, a total of approximately 3000 participants will be enrolled from around 80 sites strategically selected from various geographic regions in China. The sites will include a mix of top-tier tertiary hospitals, regional medical centers, and representative secondary hospitals to accurately reflect real-world clinical practice at different levels of care. All enrolled participants will be followed up to 96 weeks according to the data collection schedule to assess long-term clinical outcomes. Investigators will obtain an informed consent from participants before screening. The CKD participants will only be considered enrolled in the study after providing written informed consent, followed by the assignment of a unique subject identifier. The data will be collected from medical records by the investigator and entered in a cloud-based electronic case report form (eCRF) using electronic data capture (EDC) system. The EDC system is a software tool designed to ensure quality assurance and facilitate data capture during the study. The data will be extracted from established medical records or other documents of the patients and transcribed to the EDC system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged ≥18 years.
  • Willing and able to provide written informed consent to participate in the study.
  • Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
  • eGFR <60 mL/min/1.73 m² for ≥3 months, OR
  • Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months

Exclusion criteria

  • Having a life-threatening comorbidity with life expectancy < 2 years.
  • Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
  • Pregnant or breastfeeding women.
  • Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
  • Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.

Treatment and study plan

Primary outcomes

  1. Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively

    Time frame: baseline

    To determine the prevalence of HP, HF, HTN, and HK among patients with CKD

  2. Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)

    Time frame: Week 0 to week 96

    To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  3. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  4. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK.

  5. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK.

  6. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.

  7. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.

  8. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

  9. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

  10. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

  11. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK.

  12. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK.

  13. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK.

  14. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK.

  15. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK.

  16. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK.

  17. Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

    Time frame: Week 0 to week 96

    To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK.

  18. Clinical outcomes of CKD patients with HK

    Time frame: Week 0 to week 96

    To describe HK outcomes of HK recurrence for all CKD patients with HK.

  19. Clinical outcomes of CKD patients with HK

    Time frame: Week 0 to week 96

    To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK.

  20. Clinical outcomes of CKD patients with HK

    Time frame: Week 0 to week 96

    To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK.

  21. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  22. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  23. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  24. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  25. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Proportion of patients achieving UACR <700 mg/g with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  26. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  27. Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

  28. Clinical indicators for CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.

  29. Clinical indicators for CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.

  30. Clinical indicators for CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN.

  31. Clinical indicators for CKD patients with HF

    Time frame: Week 0 to week 96

    To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF.

Secondary outcomes

  1. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of eGFR slope between CKD patients with or without HP, HF, HTN, HK

  2. The HCRU among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To describe healthcare resource utilization (HCRU) among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  3. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicators eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  4. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Composite outcome of eGFR decline ≥50% between CKD patients with or without HP, HF, HTN, HK

  5. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of Change in eGFR from baseline over time between CKD patients with or without HP, HF, HTN, HK

  6. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in UACR from baseline over time between CKD patients with or without HP, HF, HTN, HK

  7. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in UPCR from baseline over time between CKD patients with or without HP, HF, HTN, HK

  8. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in UPER from baseline over time between CKD patients with or without HP, HF, HTN, HK

  9. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving UACR <700 mg/g with ≥30% reduction over time between CKD patients with or without HP, HF, HTN, HK

  10. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of Proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time between CKD patients with or without HP, HF, HTN, HK

  11. Clinical indicators of CKD patients and CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of Change in systolic BP from baseline over time between CKD patients with or without HP, HTN

  12. Clinical indicators of CKD patients and CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in diastolic BP from baseline over time between CKD patients with or without HP, HTN

  13. Clinical indicators of CKD patients and CKD patients with HP and HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving BP control target over time between CKD patients with or without HP, HTN

  14. Clinical indicators of CKD patients and CKD patients with HF

    Time frame: Week 0 to week 96

    To compare the clinical indicators of Change of NT-proBNP from baseline over time between CKD patients with or without HF

  15. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  16. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  17. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  18. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  19. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of proportion of patients achieving UACR <700 mg/g with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  20. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  21. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

  22. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in systolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN

  23. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change in diastolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN

  24. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of Proportion of patients achieving BP control target over time in patients with CKD overall, and in subgroups with HP,HTN

  25. The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF

    Time frame: Week 0 to week 96

    To identify the factors associated with the clinical indicator of change of NT-proBNP from baseline over time in patients with CKD overall, and in subgroups with HF

  26. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the composite outcome of eGFR decline ≥50% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  27. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the composite outcome of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  28. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the composite outcome of renal death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  29. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the composite outcome of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  30. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the renal outcomes of ≥50% eGFR decline from baseline in patients with CKD overall, and in subgroups with HP,HTN

  31. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the renal outcomes of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  32. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the renal outcomes of RRT in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  33. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with the renal outcomes of CKD stage progression in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  34. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with renal-related death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  35. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with CV outcomes of MACE in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  36. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with CV outcomes of HF in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  37. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with CV outcomes of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  38. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with CV outcomes of all-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  39. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with CV outcomes of all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  40. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

    Time frame: Week 0 to week 96

    To identify the factors associated with HK outcomes of HK recurrence in patients with CKD overall, and in subgroups with HK

  41. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

    Time frame: Week 0 to week 96

    To identify the factors associated with HK outcomes of severe HK requiring hospitalisation in patients with CKD overall, and in subgroups with HK

  42. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

    Time frame: Week 0 to week 96

    To identify the factors associated with HK outcomes of severe HK requiring emergency-department visits in patients with CKD overall, and in subgroups with HK

  43. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of composite outcome of ESRD between CKD patients with or without HP, HF, HTN, HK

  44. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of composite outcome of renal death between CKD patients with or without HP, HF, HTN, HK

  45. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of composite outcome of CV death between CKD patients with or without HP, HF, HTN, HK

  46. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Renal outcomes of ≥50% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK

  47. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Renal outcomes of ESRD between CKD patients with or without HP, HF, HTN, HK

  48. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Renal outcomes of RRT between CKD patients with or without HP, HF, HTN, HK

  49. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of CKD stage progression between CKD patients with or without HP, HF, HTN, HK

  50. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Renal-related death between CKD patients with or without HP, HF, HTN, HK

  51. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of CV outcomes of MACE between CKD patients with or without HP, HF, HTN, HK

  52. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of CV outcomes of hHF between CKD patients with or without HP, HF, HTN, HK

  53. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of All-cause death between CKD patients with or without HP, HF, HTN, HK

  54. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of All-cause hospitalization between CKD patients with or without HP, HF, HTN, HK

  55. Clinical outcomes of CKD patients and CKD patients with HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of HK recurrence between CKD patients with or without HK

  56. Clinical outcomes of CKD patients and CKD patients with HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Severe HK requiring hospitalisation between CKD patients with or without HK

  57. Clinical outcomes of CKD patients and CKD patients with HK

    Time frame: Week 0 to week 96

    To compare the clinical outcomes of Severe HK requiring emergency-department visits between CKD patients with or without HK

  58. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time between CKD patients with or without HP, HF, HTN, HK

  59. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with All-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

  60. The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

    Time frame: Week 0 to week 96

    To identify the factors associated with all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Other outcomes

  1. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of eGFR slope under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  2. The HCRU among patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To compare the HCRU in CKD patients with or without HP, HF, HTN or HK

  3. The HCRU among patients with CKD overall, and in subgroups

    Time frame: Week 0 to week 96

    To compare the HCRU under different treatment in CKD patients with HP, HF, HTN or HK

  4. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the composite outcome of eGFR decline ≥50% between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  5. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the composite outcome of eGFR decline ≥50% under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  6. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in eGFR from baseline over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  7. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in UACR from baseline over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  8. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in UPCR from baseline over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  9. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving UACR <700 mg/g with ≥30% reduction over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  10. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  11. Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  12. Clinical indicators of CKD patients and CKD patients with HP, HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in systolic BP from baseline over time under different treatment in CKD patients and CKD patients with HP, HTN

  13. Clinical indicators of CKD patients and CKD patients with HP, HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change in diastolic BP from baseline over time under different treatment in CKD patients and CKD patients with HP, HTN

  14. Clinical indicators of CKD patients and CKD patients with HP, HTN

    Time frame: Week 0 to week 96

    To compare the clinical indicators of proportion of patients achieving BP control target over time under different treatment in CKD patients and CKD patients with HP, HTN

  15. Clinical indicators of CKD patients and CKD patients with HF

    Time frame: Week 0 to week 96

    To compare the clinical indicators of change of NT-proBNP from baseline over time under different treatment in CKD patients and CKD patients with HF

  16. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the composite outcome of ESRD under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  17. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the composite outcome of RRT under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  18. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the composite outcome of CKD stage progression under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  19. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the composite outcome of Renal-related death under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  20. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the CV outcomes of MACE under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  21. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the CV outcomes of hHF under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  22. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare the CV outcomes of CV death under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  23. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare All-cause death under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  24. Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

    Time frame: Week 0 to week 96

    To compare All-cause hospitalization under different treatment in CKD patients and CKD patients with HP, HF, HTN or HK

  25. Clinical outcomes of CKD patients and CKD patients with HK

    Time frame: Week 0 to week 96

    To compare HK recurrence under different treatment in CKD patients and CKD patients with HK

  26. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the composite outcome of ESRD between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  27. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the composite outcome of renal death between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  28. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the composite outcome of CV death between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  29. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the renal outcomes of ≥50% eGFR decline from baseline between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  30. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the renal outcomes of ESRD between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  31. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the renal outcomes of RRT between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  32. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the renal outcomes of CKD stage progression between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  33. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the renal outcomes of Renal-related death between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  34. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the CV outcomes of MACE between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  35. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the CV outcomes of hHF between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  36. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the CV outcomes of CV death between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  37. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the All-cause death between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

  38. Clinical outcomes of CKD patients in nephrology clinics and non-nephrology clinics

    Time frame: Week 0 to week 96

    To compare the All-cause hospitalization between CKD patients managed in nephrology clinics and non-nephrology clinics , if available

Study contacts

Contact information is provided by the study sponsor or research team.

AstraZeneca Clinical Study Information Center

CONTACT

[email protected]

1-877-240-9479

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 19, 2026
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.